NCT00077766 - A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients. | Biotech Hunter

Enrollment

313

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions

Anemia

Interventions

DRUG

Darbepoetin alfa

Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.

DRUG

methoxy polyethylene glycol-epoetin beta [Mircera]

RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).

Trial Locations (48)

1003

Lausanne

1070

Brussels

1200

Brussels

1871

Sydney

2250

Gosford

3050

Parkville

3168

Clayton

4000

Liège

Roskilde

4102

Brisbane

5000

Odense

5001

Aarau

8036

Graz

9100

Aalborg

9300

Aalst

10004

Córdoba

18288

Stockholm

23900

Lecco

24100

Bergamo

27100

Pavia

28035

Madrid

31077

Toulouse

33006

Oviedo

34295

Montpellier

34346

Hannoversch Münden

37008

Salamanca

39008

Santander

57100

Livorno

65013

Tarbes

65185

Karlstad

67091

Strasbourg

78054

Villingen-Schwenningen

90431

Nuremberg

93307

Aubervilliers

98158

Messina

NSW 2148

Blacktown

T2N 2T9

Calgary

T6G 2B7

Edmonton

V2C 2T1

Kamloops

V5Z 1M9

Vancouver

R3A 1R9

Winnipeg

B3H 1V8

Halifax

N2G 1N9

Kitchener

L5M 2V8

Mississauga

00029

HUS

06002

Nice

08915

Badalona

08036

Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY